Voyager Therapeutics (NASDAQ: VYGR)
Voyager Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Voyager Therapeutics Company Info
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
News & Analysis
2 Biotech Stocks That Could Make You Richer
These biotech companies are seeing a spike in revenue growth.
Why Voyager Therapeutics Stock Is Sinking This Week
Investors are taking profits on this red-hot stock this week.
Pfizer and Novartis Are Betting On This Under-the-Radar Biotech. Should You?
Voyager Therapeutics has promising technology. But the stock is very risky.
Why Voyager Therapeutics Stock Is Sinking Today
A clinical hold is weighing on the biotech's shares today.
Parkinson's Disease Patients Get Long-Term Benefits from Experimental Gene Therapy
Three years after treatment with NBIb-1817, Parkinson's disease patients still are still showing improvements.
Is Now a Good Time To Buy Neurocrine Biosciences?
The biopharmaceutical company has seen shares rise 44.5% in less than two months.
3 Biotechs That Have Doubled This Year (Acquisition Next?)
Good news has a way of attracting suitors.
Here's Why Voyager Therapeutics Rose as Much as 13% Today
The gene therapy company saw another peer get gobbled up in an acquisition.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.